Atara Biotherapeutics Inc (NASDAQ:ATRA) Expected to Announce Earnings of -$1.40 Per Share

Equities research analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings of ($1.40) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.45) and the highest estimate coming in at ($1.36). Atara Biotherapeutics reported earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 8.5%. The business is expected to report its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.71) per share for the current fiscal year, with EPS estimates ranging from ($5.87) to ($5.51). For the next year, analysts anticipate that the business will report earnings of ($5.39) per share, with EPS estimates ranging from ($5.93) to ($4.83). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.15).

A number of equities research analysts have commented on ATRA shares. Mizuho set a $43.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Citigroup set a $14.00 target price on shares of Atara Biotherapeutics and gave the stock a “hold” rating in a research report on Monday, August 12th. Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, September 13th. Stifel Nicolaus set a $36.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Goldman Sachs Group cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $14.00 to $9.00 in a research note on Friday, September 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $29.75.

In other news, insider Joe Newell sold 3,500 shares of Atara Biotherapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $13.51, for a total transaction of $47,285.00. Following the transaction, the insider now owns 57,998 shares in the company, valued at approximately $783,552.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRA. Marshall Wace LLP purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $284,000. Marshall Wace North America L.P. purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $1,961,000. FMR LLC lifted its stake in shares of Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after buying an additional 1,143,787 shares in the last quarter. Coronation Fund Managers Ltd. lifted its stake in shares of Atara Biotherapeutics by 174.6% during the 2nd quarter. Coronation Fund Managers Ltd. now owns 92,050 shares of the biotechnology company’s stock valued at $1,851,000 after buying an additional 58,530 shares in the last quarter. Finally, Aperio Group LLC purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at $63,000. Institutional investors own 91.79% of the company’s stock.

NASDAQ:ATRA opened at $12.35 on Wednesday. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics has a 12 month low of $11.50 and a 12 month high of $43.94. The company has a market cap of $663.67 million, a PE ratio of -2.34 and a beta of 2.09. The company has a 50 day simple moving average of $14.04 and a two-hundred day simple moving average of $20.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News